About this trial
There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.
Eligibility criteria
Qualifiers
Age 18 to 38 years old.
Normal Menstrual cycle of 25-35 days.
Body Weight 60to90 kg
AMH>1.3 - <3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of >5 on menstrual cycle days 2-3,
Disqualifiers
History of premature ovulation
Azoospermia
PCOS
Endometriosis AFS ¾
Trial design
Treatments tested in this trial
- Ovarian stimulation with menstruation or after ovulation